Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2020-04-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于公司2019年限制性股票激励计划第一个解除限售期解除限售及回购注销部分限制性股票相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2019 restricted stock incentive plan of Xiamen Aide Biomedical Technology Co., Ltd. It discusses the first unlocking period of restricted stock, the conditions for unlocking, repurchase and cancellation of some restricted stocks, and the legal compliance of these actions. The document references specific legal regulations and company board and shareholder meeting approvals related to the stock incentive plan. It is not a financial report, earnings release, or management discussion, but a legal opinion on a corporate stock incentive matter. This type of document fits best under Regulatory Filings (RNS) as it is a legal opinion letter related to corporate governance and compliance, not a standalone audit report or a full annual report. The document length is about 7,000 characters, and it contains detailed legal analysis rather than just an announcement or a brief summary, so it is not a Report Publication Announcement (RPA). Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-04-13 Chinese
上海荣正投资咨询股份有限公司关于公司2019年限制性股票激励计划第一个限售期解除限售相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2019 Restricted Stock Incentive Plan of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. It discusses the approval, authorization, and conditions for the first lock-up period release of restricted stocks. The report includes detailed analysis of the incentive plan, performance conditions, and compliance with relevant laws and regulations. It is not a general annual or interim financial report, nor is it a simple announcement or certification. The content focuses on the stock incentive plan and related financial advisory opinions, which aligns with a Capital/Financing Update category as it deals with stock incentives and related capital matters.
2020-04-13 Chinese
关于回购注销2019年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from a company regarding the repurchase and cancellation of restricted stock under a 2019 restricted stock incentive plan. It details the number of shares repurchased, the price, the approval process, and the impact on the company's share structure. It includes board and supervisory committee approvals, independent director opinions, and legal opinions. The document is focused on a share repurchase related to an incentive plan, not a full financial report or earnings release. It is not a report publication announcement or a certification. The content fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or cancellations of its own shares.
2020-04-13 Chinese
中信证券股份有限公司关于公司终止部分募集资金投资项目并将剩余募集资金用于永久补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the termination of part of the fundraising investment projects by Xiamen Ed Bio-Medical Technology Co., Ltd. and the use of the remaining raised funds for permanent replenishment of working capital. It references specific fundraising projects, amounts, approvals by the board, supervisory board, and independent directors, and compliance with regulatory guidelines. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a formal audit or verification opinion related to the use of raised funds, which fits the category of an Audit Report / Information (AR). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. Q1 2020
2020-04-13 Chinese
关于将部分募投项目结项并使用节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the completion of certain fundraising investment projects and the permanent use of surplus raised funds to supplement working capital. It details the original fundraising, the use and management of the funds, the surplus generated, and the approvals from the board, supervisory committee, independent directors, and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but rather focuses on the use of raised capital and related approvals. It is a typical capital/financing update about the use of fundraising proceeds and changes in capital allocation. The document length is 3643 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-04-13 Chinese
中信证券股份有限公司关于公司2019年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2019 annual special audit of the fundraising funds' deposit and usage by Xiamen Aide Biomedical Technology Co., Ltd. It includes specific financial figures about the amount raised, usage, balance, investment projects, changes in project funding, and compliance with regulatory requirements. The document references regulatory guidelines and includes an auditor's opinion on the compliance and accuracy of the fundraising funds' management. It is not a general annual report or earnings release but a specialized audit report focused on the use and management of raised funds. The document length is over 11,000 characters and contains substantive financial data and analysis. Therefore, it fits the category of an Audit Report / Information (AR) rather than a simple announcement or regulatory filing. FY 2019
2020-04-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.